Caitlin Farabaugh
Gynecologic Oncology · Wynnewood, PANPI 1073787750
Payments from drug & device makers
What this record shows
This record is dominated by education: $3,020 of the $3,606 with a category attached, or 83.8%. Intuitive Surgical accounts for 87.4% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $3,000 and has fallen 92.5% since, to $226 in 2025.
Across 15 payments — averaging $240.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- AbbVie$125
- Merck$115
- Eisai Inc.$54
- Caris MPI, Inc.$27
- GSK$25
- plus $110 from 5 others
Across 3 payments — averaging $18,503 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$38K
- Merck$17K
What the payments were for
- Food & beverage$58516%
- Education$3,02084%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 3 | $3,150 |
| AbbVie | 1 | $125 |
| Merck | 2 | $115 |
| Eisai Inc. | 2 | $54 |
| Caris MPI, Inc. | 1 | $27 |
| GSK | 1 | $25 |
| Tempus AI, Inc | 1 | $24 |
| Novartis | 1 | $24 |
| Genmab U.S., Inc. | 1 | $22 |
| Clovis Oncology, Inc. | 1 | $20 |
| AstraZeneca | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$3,000
- Elahere$125
How this compares
$3,606 in reported general payments places this provider in the 70th percentile of 90 gynecologic oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 11 | $72 |
| Oxycodone Hcl | 20 | $40 |
| Tramadol Hcl | 22 | $19 |
| Amlodipine Besylate | 11 | $18 |
Paid to pharmacies, not to this prescriber.
Other gynecologic oncology in Wynnewood
- Charles DuntonWynnewood$309K
- David HoltzWynnewood$3K
- Marianne Hom-TedlaWynnewood$1K
- Jharna PatelWynnewood$1K
- Sudeshna Chatterjee-PaerWynnewood$1K
- Xiaomang SticklesWynnewood$1K
- Norman RosenblumWynnewood$687
- Lauren TurkerWynnewood$466
- Thomas KrivakPittsburgh$1.6M
- Mark ShahinHershey$914K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.